1.29
0.00 (0.00%)
| Previous Close | 1.29 |
| Open | 1.30 |
| Volume | 11,234,045 |
| Avg. Volume (3M) | 3,462,269 |
| Market Cap | 1,023,038,336 |
| Price / Sales | 1.28 |
| Price / Book | 0.660 |
| 52 Weeks Range | |
| Earnings Date | 5 Aug 2025 - 11 Aug 2025 |
| Profit Margin | -5.66% |
| Operating Margin (TTM) | -44.79% |
| Diluted EPS (TTM) | -0.060 |
| Quarterly Revenue Growth (YOY) | -13.70% |
| Total Debt/Equity (MRQ) | 37.58% |
| Current Ratio (MRQ) | 2.49 |
| Operating Cash Flow (TTM) | -182.48 M |
| Levered Free Cash Flow (TTM) | -107.74 M |
| Return on Assets (TTM) | -8.20% |
| Return on Equity (TTM) | -3.04% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Bearish | Bearish |
| Diagnostics & Research (Global) | Bearish | Bearish | |
| Stock | Opko Health, Inc. | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Average | 1.38 |
|
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Value |
| % Held by Insiders | 46.81% |
| % Held by Institutions | 31.12% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 3.00 (HC Wainwright & Co., 132.56%) | Buy |
| Median | 2.63 (103.88%) | |
| Low | 2.25 (Barrington Research, 74.42%) | Buy |
| Average | 2.63 (103.88%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 1.44 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Barrington Research | 01 May 2025 | 2.25 (74.42%) | Buy | 1.35 |
| HC Wainwright & Co. | 07 Apr 2025 | 3.00 (132.56%) | Buy | 1.53 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |